IBRX FY 2017 Earnings — ImmunityBio, Inc. Revenue & Financial Results | Market Cap Arena

IBRXImmunityBio, Inc.

$8B

FY 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$45,000+2.3% YoY

Gross Profit

$45,000100.0% margin

Operating Income

-$99M-220266.7% margin

Net Income

-$96M-214273.3% margin

EPS (Diluted)

$-0.30

Cash Flow

Operating Cash Flow

-$49M

Free Cash Flow

-$84M

Stock-Based Comp.

$37M

Balance Sheet

Total Assets

$250M

Total Liabilities

$32M

Stockholders' Equity

$219M

Cash & Equivalents

$24M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$45,000	$44,000	+2.3%
Gross Profit	$45,000	$44,000	+2.3%
Operating Income	-$99M	-$125M	+20.4%
Net Income	-$96M	-$121M	+20.2%